CO-Sprout: Broccoli sprout powder pilot trial for COVID-19 positive pregnant women on the duration of symptoms
CO-Sprout: A pilot double-blinded randomised control trial of broccoli sprout powder supplementation for pregnant women with COVID-19 on the duration of symptoms
Monash Health
60 participants
Aug 23, 2022
Interventional
Conditions
Summary
CO-Sprout clinical trial will investigate whether broccoli sprout powder capsules given to pregnant women infected with SARS-CoV-2 (COVID-19) can help reduce the duration of COVID-19 associated symptoms. Additional outcomes measured will include hospital admissions, maternal respiratory outcomes, obstetric and birthing outcomes, as well as neonatal outcomes. It is hoped that providing pregnant women with this natural supplement during COVID-19 infection, will help reduce the levels of inflammation and improve their symptoms hopefully leading to reduced need for hospital and ICU admissions. Broccoli sprout powder contains the naturally occurring phytonutrient sulforaphane which is hoped to improve maternal and neonatal outcomes during pregnancy from infection with the SARS-CoV-2 virus.
Eligibility
Inclusion Criteria7
- Currently pregnant with singleton gestation from 20+0 - 36+0 weeks
- Positive COVID-19 test including (viral polymerase chain reaction (PCR) positive test for SARS-CoV-2) or positive rapid antigen test (RAT) within 5 days
- Unvaccinated, partially, fully (+/- booster dose) vaccinated against COVID-19
- Signs or symptoms of COVID-19 that began less than or equal to 7 days of trial recruitment including but not limited to shortness of breath, anosmia, fevers, sore throat, headache and myalgia
- Able to tolerate oral supplementation and willing to complete the expected 14 day course
- Deemed capable of understanding the information provided and able to give written informed consent (with interpreter use as required).
- greater than or equal to 18 years of age
Exclusion Criteria7
- Current use of broccoli or broccoli sprout supplement
- Contraindications to use (e.g., intolerance of broccoli)
- Significant uncertainty in ensuring gestational age is within limits
- Unwillingness or inability to follow the procedures outlined in the PICF (patient information consent form)
- Mentally, cognitively or legally incapacitated or ineligible to provide informed consent
- Co-recruitment/participation in another clinical trial where there is a pharmaceutical or herbal or nutritional intervention (such trial interventions would also include: multi-vitamins, minerals, antiviral, immunomodulatory or complementary and alternative medicines)
- Current antibiotic, antiviral or monoclonal antibody treatment related to acute illness at time of recruitment
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Broccoli sprout powder capsules (producing 21mg sulforaphane) Oral 2 capsules (10.5mg sulforaphane) twice a day, morning and night (BD). Total daily dose 42mg of sulforaphane daily The administration of the trial intervention will cease after 14 days of treatment or in the event the patient is unable to continue oral supplementation Adherence to trial intervention will be measured by return of capsules at end of trial and with use of a study participant drug diary
Locations(4)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12622000173796